CVS Health Ventures’ participation in Simile’s Series B highlights payer and provider appetite for synthetic-user platforms that simulate patient or customer behavior before expensive live experiments. The healthcare angle sits beside Simile’s wider enterprise story and $2 billion valuation narrative. It matters because regulated industries are testing digital twins of people, not only customer-support chatbots. Caveat: privacy, bias and clinical validity questions grow quickly when synthetic cohorts begin to inform real care or coverage decisions.